Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
Date:10/9/2008

CALGARY, Oct. 9 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 16th Annual BioPartnering Europe conference in London, U.K. on Monday, October 13 at 2 p.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 12-14, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
2. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
3. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
4. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
5. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
10. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
11. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... NE (PRWEB) , ... December 07, 2016 , ... ... systems integration, today announced that it has become a Wonderware Certified System Integrator ... System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner certification ...
(Date:12/7/2016)... 2016  Biocom, the association for the California ... passage of 21 st Century Cures legislation in Congress. ... a 392-26 vote and in the Senate on December 7 ... Joe Panetta , president & CEO of Biocom: ... to millions of patients around the world. The measure culminates ...
(Date:12/7/2016)... ARBOR, Mich. , Dec. 7, 2016  Lycera ... modulatory medicines, announced today the initiation of a Phase ... LYC-30937- E nteric C oated, in patients with ... is estimated to affect as many as 7.5 million people ... approximately 1.5 - 3 million cases being diagnosed as ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
Breaking Biology News(10 mins):